Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVT05
- Development stage
- Phase 3
- Lead developer
- Alvotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
AVT05 is a proposed biosimilar to Simponi and Simponi Aria, which are brand names for golimumab, a monoclonal antibody that targets and inhibits tumor necrosis factor alpha (TNF alpha), a cytokine involved in systemic inflammation. By inhibiting TNF alpha, golimumab reduces inflammation associated with several chronic inflammatory diseases. AVT05 is being developed by Alvotech in partnership with Teva Pharmaceuticals for the US market and Advanz Pharma for Europe. It is intended to treat conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory diseases. As of early 2025, AVT05 has not received regulatory approval but has demonstrated therapeutic equivalence to Simponi in clinical trials[1][2][4][6].
- Brand names
- Gobivaz
- Other names
- Golimumab biosimilar (Alvotech)
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on AVT05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVT05.